R-ACVBP Versus R-CHOP in Patients Aged 60-65 With Diffuse Large B-cell Lymphoma

August 21, 2018 updated by: Lymphoma Study Association

Randomized Study of ACVBP Plus Rituximab Versus CHOP Plus Rituximab in Non Previously Treated Patients Aged From 60 to 65 Years With Diffuse Large B-Cell Lymphoma

The primary objective of this study is to evaluate the efficacy of doxorubicin, cyclophosphamide, vindesine, bleomycin, and prednisone (ACVBP) plus rituximab in comparison to cyclophosphamide, doxorubicin, vincristine, prednisone (CHOP) plus rituximab in patients aged from 60 to 65 years with non-previously treated diffuse large B-cell lymphoma as measured by the event-free survival. The goal is to obtain a 10% increase of event-free survival at 3 years.

Study Overview

Detailed Description

In Europe, 50% or more of new non-Hodgkin lymphoma cases occur in patients older than 60 years. More than 30% are diffuse large B-cell lymphomas (DLCL).

The CHOP chemotherapy (cyclophosphamide, doxorubicin, vincristine, prednisone) was considered as the standard treatment in this population. Nevertheless, this treatment is associated with some toxic events in elderly patients and it did does not succeed to increase the 3-year survival rate above 40%.

Two trials in patients above 60 years with DLCL cases were conducted by the GELA in the aim to improve the results of CHOP.

Protocol LNH 93-5 : The primary objective of this study was to compare CHOP to ACVBP in patients aged from 61 to 69 years with aggressive lymphoma and at least one adverse prognostic factor according to the International Prognostic Index.

Unlike the CHOP regimen, the ACVBP regimen includes a more intensive induction followed by a sequential consolidation with drugs different from those used during the induction phase, and includes a prevention of neuromeningeal relapses.

Out of 708 patients included in this study, the results have shown that:

  • Complete response rate was the same in the two arms.
  • Event free survival was significantly better in the ACVBP arm than the CHOP arm ( 5-year survival rate : 39% versus 29%, p=0.005).
  • Overall survival was significantly better in the ACVBP arm than in the CHOP arm (the 5-year survival rate : 46% versus 38%, p=0.036).
  • The ACVBP regimen was more toxic than the CHOP regimen, particularly in elderly patients (> 65 years) and in patients with a low performance status.
  • Prevention of neuromeningeal relapses was necessary for these patients.

Protocol LNH 98-5, the objective of this study was to compare the association CHOP + rituximab (R-CHOP) to the CHOP regimen alone in elderly patients with non previously treated diffuse large B-cell lymphoma.

Long-term results based on data from 399 patients, with a median follow-up of 5 years were as follows :

  • Complete response rate was better in the R-CHOP arm than in the CHOP arm (76% versus 61%, p<0.005).
  • Significant prolongation of event-free survival (p<0.0002) and overall survival (p<0.0073) in the R-CHOP arm.
  • No significant difference between the two arms in terms of toxicity. R-CHOP is now considered worldwide as the standard combination for these patients.

These conclusions invited us to propose a randomized trial comparing ACVBP + rituximab to CHOP + rituximab. The study population is limited to patients aged from 60 to 65 years.

Study Type

Interventional

Enrollment (Actual)

138

Phase

  • Phase 3

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Yvoir, Belgium
        • Groupe d'Etude des Lymphomes de l'Adulte
      • Créteil, France, 94010
        • Hopital Henri Mondor
      • Paris, France, 75010
        • Hopital Saint Louis
      • Pierre-Bénite cedex, France, 69495
        • Service d'Hématologie - Centre Hospitalier Lyon-Sud
      • Reims, France, 51092
        • Centre Hospitalier Robert Debre
      • Rouen, France, 76038
        • Centre Henri Becquerel
      • Villejuif, France
        • Institut Gustave Roussy
      • Lausanne, Switzerland
        • Schweirische Arbeitsgruppe fur klinische Krebsforschung

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

60 years to 65 years (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Patient with diffuse large B-cell lymphoma according to the WHO classification (anti CD20 labeling)
  • Aged from 60 to 65 years.
  • Not previously treated.
  • Ann Arbor stage II, III, IV.
  • ECOG performance status 0 to 2.
  • Minimum life expectancy of 3 months.
  • Negative HIV, hepatitis B virus (HBV) and hepatitis C virus (HCV) serologies test 4 weeks (except after vaccination).
  • Having previously signed a written informed consent.

Exclusion Criteria:

  • T-cell lymphoma.
  • Any history of treated or non-treated indolent lymphoma. However, patients not previously diagnosed and having a diffuse large B-cell lymphoma with some small cell infiltration in bone marrow or lymph node may be included.
  • Central nervous system or meningeal involvement by lymphoma.
  • Contra-indication to any drug contained in the chemotherapy regimens.
  • Any serious active disease (according to the investigator's decision).
  • Poor renal function (creatinine level>150micromol/l), poor hepatic function (total bilirubin level>30mmol/l, transaminases>2.5 maximum normal level) unless these abnormalities are related to the lymphoma.
  • Poor bone marrow reserve as defined by neutrophils<1.5G/l or platelets<100G/l, unless related to bone marrow infiltration.
  • Any history of cancer during the last 5 years with the exception of non-melanoma skin tumors or stage 0 (in situ) cervical carcinoma.
  • Treatment with any investigational drug within 30 days before planned first cycle of chemotherapy and during the study.
  • Adult patient under tutelage.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: R-ACVBP
Rituximab, Doxorubicin, Cyclophosphamide, Vindesine, Bleomycin, Prednisone
375 mg/m², D1, 4 cycles
75 mg/m², D1, 4 cycles
1200 mg/m², D1, 4 cycles
2 mg/m², D1, D5, 4 cycles
10 mg, D1, D5, 4 cycles
60 mg, D1-D5, 4 cycles
40 mg, D1-D5, 4 cycles
50 mg/m², D1, 4 cycles
750 mg/m², D1, 4 cycles
Active Comparator: R-CHOP
Rituximab, Doxorubicin, Cyclophosphamide, Vincristine, Prednisone
375 mg/m², D1, 4 cycles
75 mg/m², D1, 4 cycles
1200 mg/m², D1, 4 cycles
60 mg, D1-D5, 4 cycles
40 mg, D1-D5, 4 cycles
50 mg/m², D1, 4 cycles
750 mg/m², D1, 4 cycles
1.4 mg/m², D1, 4 cycles

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
event free survival
Time Frame: 8 years (end of study)
percentage of patients alive with no event
8 years (end of study)

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
complete response rate
Time Frame: 8 years (end of study)
percentage of patients with complete response
8 years (end of study)
progression rate
Time Frame: 8 years (end of study)
percentage of patients with progression
8 years (end of study)
relapse rate
Time Frame: 8 years (end of study)
percentage of patients with relapse
8 years (end of study)
disease-free survival for complete responders
Time Frame: 8 years (end of study)
percentage of patients with complete response who remain disease-free
8 years (end of study)
overall survival
Time Frame: 8 years (end of study)
percentage of patients alive
8 years (end of study)
neuromeningeal relapse rate
Time Frame: 8 years (end of study)
percentage of patients with neuromeningeal relapse
8 years (end of study)
number of SAE
Time Frame: 8 years (end of study)
8 years (end of study)

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Collaborators

Investigators

  • Principal Investigator: Herve Tilly, MD, Lymphoma Study Association

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

October 16, 2001

Primary Completion (Actual)

April 27, 2010

Study Completion (Actual)

April 27, 2010

Study Registration Dates

First Submitted

August 25, 2005

First Submitted That Met QC Criteria

August 25, 2005

First Posted (Estimate)

August 26, 2005

Study Record Updates

Last Update Posted (Actual)

August 23, 2018

Last Update Submitted That Met QC Criteria

August 21, 2018

Last Verified

August 1, 2018

More Information

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe